Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Ramelteon

Drug and asset intelligence for Ramelteon with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
2
Stage
Development stage unavailable

Sponsor company

Micro Labs →

Mechanism of action

Melatonin Receptor Agonist

Recent signals(2)

RegulatoryJuly 3, 2026

FDA Accepts Supplement Application for Ramelteon by Micro Labs

The FDA has accepted a supplemental application for Ramelteon submitted by Micro Labs.

StrategyJune 30, 2026

FDA Grants Approval for Ramelteon ANDA215485 by Hibrow Healthcare

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 215485 for Ramelteon submitted by Hibrow Healthcare.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

(2)

Topline Data

Micro Labs — Ramelteon

Monitor the review progress and any subsequent approval announcements from the FDA.

July 3, 2026 · N/A

Topline Data

— Ramelteon

Monitor market entry timelines and any subsequent competitive responses from established players in the sleep disorder market.

June 30, 2026 · N/A

Indications

Sleep Disorders →

Therapeutic areas

Melatonin Receptor Agonist →
Sleep Disorders →
Sleep Disorders · Melatonin Receptor Agonist →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.